Several inhibitors of IGF-1R, including monoclonal antibodies and small molecule tyrosine kinase inhibitors, have entered clinical development for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and ovarian carcinoma (OC) [22]. Here, IGF1R is linked to non-small cell lung carcinoma.